GlaxoSmithKline has become the first company to license the Rosetta Resolver Software Development Kit version 2.0.
The kit will allow GlaxoSmith- Kline, which already has licensed Rosettas flagship Rosetta Resolver microarray data analysis software, to customize Resolver for its own research.
According to Rosetta Biosoftware, Software Development Kit (SDK) users can incorporate their own error models and clustering algorithms via the systems open application program interfaces [APIs]. Error models are plugged in using Java technology, while clustering algorithms are incorporated using both C++ and Java.
The Rosetta Resolver SDK will allow us to access the Rosetta Resolver systems open APIs, stated Paul Matthews, project leader of gene expression bioinformatics at GlaxoSmithKline. Our internal bioinformatics staff will make use of the open APIs to extend the system and integrate it with our internally developed algorithms and bioinformatics solutions.
This agreement signals not only Rosetta Resolvers continuing popularity among pharmaceutical companies, but also pharmas confidence that Rosettas Biosoftware division is separate enough from Merck, which owns Rosetta Inpharmatics, to ensure that data will be secure.
Glaxos data will be accessible to the Biosoftware division, but not accessible to Merck, said Myra Ozaeta, a spokeswoman for Rosettas Biosoftware division. Legal documents protect this [arrangement].
Rosetta officially launched the Biosoftware division on September 20, and appointed Doug Bassett as vice president and general manager. The division recently moved to its new headquarters in Kirkland, Wash., a short distance from Rosetta Inpharmatics offices.
The Biosoftware division aims to operate quasi-independently of Merck, and is free to license the software and form contracts with Mercks competitors. They understand that in order to keep our products successful, we need to do business with customers the way we used to, Ozaeta said.
The company did not disclose financial details of the agreement.